In this free webinar, learn how advanced robotics, digital tools and design of experiments (DoE) are revolutionizing viral vector manufacturing, optimization and quality control (QC) release testing. Attendees will learn about an advanced digital and physical platform, integrated with automated liquid handlers, which enables automated DoE and multivariate system optimisation. The featured speakers will discuss the evolution of automated analytical workflows for qPCR, ELISA and cell-based assays. Attendees will learn about the critical role of plasmid DNA concentration and ratio adjustments in improving titres for lentiviral vectors. The speakers will share how DoE and multivariate systems optimization accelerate the identification of optimal production parameters, enabling faster, more efficient development of cost-effective and scalable viral vector drug products.
TORONTO, Nov. 19, 2024 /PRNewswire-PRWeb/ -- The production and commercialisation of advanced therapy medicinal products (ATMPs) such as lentiviral vectors present unique challenges in design, production, purification and quality control (QC) release testing when compared to traditional pharmaceutical compounds and even other biologics such as monoclonal antibodies.
Optimal production is heavily dependent on the concentration and ratios of the plasmid DNA components contributing to the transfection process. Improving titres can determine whether a new gene therapy product is commercially viable. A considerable amount of research is aimed at establishing the best titre and one of the ways to do this is by ensuring optimal transfection ratios that can improve the productivity or recovery of upstream/downstream platform processes.
Furthermore, many of the analytical methods employed require days or weeks to complete often with multi-step cell culture combined with quantitative readouts. Lengthy protocols, operator-to-operator variability and a heavy dependence on manual setup are common shortfalls.
Lab-based robotics and digital tools enable bench scientists to work more efficiently, generate more robust data and reduce time-to-insight. Automation in both research and good manufacturing practice (GMP)-regulated environments increases assay throughput, robustness, repeatability and reduces operator's hands-on-time. Moreover, design of experiments (DoE) and multivariate systems optimisation helps identify optima at a speed that would be impossible using manual methods. Such cutting-edge ways of working help reduce time-to-market and deliver scalable, cost-effective, viral vector drug products.
Register for this webinar to explore how advanced robotics, digital tools and design of experiments are revolutionizing viral vector manufacturing, optimization and QC release testing.
Join experts from OXB, André Raposo, PhD, Director, Innovation Department; Gareth McCathie, PhD, Group Lead; Thomas Evans, Principal Scientist, for the live webinar on Monday, December 9, 2024, at 11am EST (4pm GMT/UK).
For more information, or to register for this event, visit Accelerating Viral Vector Manufacturing: The Use of Automation from Early Stage to QC Release.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com/
SOURCE Xtalks
Share this article